tiprankstipranks
Zevra Therapeutics announces U.S. commercial availability of MIPLYFFA
PremiumThe FlyZevra Therapeutics announces U.S. commercial availability of MIPLYFFA
2M ago
Zevra Therapeutics price target lowered to $23 from $25 at Canaccord
Premium
The Fly
Zevra Therapeutics price target lowered to $23 from $25 at Canaccord
2M ago
Zevra Therapeutics’ Transformative Third Quarter 2024
Premium
Company Announcements
Zevra Therapeutics’ Transformative Third Quarter 2024
2M ago
Zevra Therapeutics initiated with a Buy at Guggenheim
PremiumThe FlyZevra Therapeutics initiated with a Buy at Guggenheim
3M ago
Zevra Therapeutics price target raised to $21 from $19 at Roth MKM
Premium
The Fly
Zevra Therapeutics price target raised to $21 from $19 at Roth MKM
4M ago
Zevra Therapeutics price target raised to $25 from $18 at Maxim
Premium
The Fly
Zevra Therapeutics price target raised to $25 from $18 at Maxim
4M ago
Zevra Therapeutics price target raised to $20 from $18 at H.C. Wainwright
PremiumThe FlyZevra Therapeutics price target raised to $20 from $18 at H.C. Wainwright
4M ago
Zevra Therapeutics receives FDA approval for Miplyffa
Premium
The Fly
Zevra Therapeutics receives FDA approval for Miplyffa
4M ago
FDA approves Zevra’s Miplyffa, first treatment for Neimann-Pick disease, type C
Premium
The Fly
FDA approves Zevra’s Miplyffa, first treatment for Neimann-Pick disease, type C
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100